Literature DB >> 22326401

FOXM1 expression correlates with tumor invasion and a poor prognosis of colorectal cancer.

Xiao-Yuan Chu1, Zi-Man Zhu, Long-Bang Chen, Jing-Hua Wang, Quan-Sheng Su, Ji-Rong Yang, Yong Lin, Li-Jun Xue, Xiao-Bei Liu, Xiao-Bei Mo.   

Abstract

FOXM1, a member of the Forkhead Box (Fox) family of transcription factors, plays a critical role in tumor development and metastasis. The aim of this study was to elucidate its role in colorectal cancer (CRC), particularly prognosis and metastasis. Semi-quantitative RT-PCR and Western blot assays were used to measure the expression levels of FOXM1 mRNA and protein in 15 CRC and adjacent normal mucosa tissues. Immunohistochemical assay was performed to detect FOXM1 protein expression in 112 CRC tissues and further determine its clinicopathological and prognostic significance. RNA interference (RNAi) was used to knockdown endogenous FOXM1 expression in CRC cell lines and to analyze the effects of FOXM1 knockdown on migration and invasion of CRC cells. The relative expression levels of FOXM1 mRNA and protein were significantly higher in CRC tissues than in adjacent normal mucosa tissues (P<0.01). In addition, the immunostaining of FOXM1 protein was stronger in CRC tissues than in adjacent normal mucosa tissues. By statistical analysis, we showed that high FOXM1 expression was closely correlated with the presence of lymph node metastasis, incidence of liver metastasis, and advanced TNM stage. Moreover, the cumulative 5-year survival rate of CRC patients with high FOXM1 expression was lower than that of those with low FOXM1 expression (P=0.0047). Multivariate analysis showed that the status of FOXM1 expression was an independent prognostic factor for CRC patients (P=0.025). Furthermore, RNAi-mediated FOXM1 knockdown could significantly inhibit growth, migration and invasion of CRC cells. Our results showed that FOXM1 over-expression is a molecular marker predicting increased invasive/metastatic potential of CRC and a poorer prognosis.
Copyright © 2012 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22326401     DOI: 10.1016/j.acthis.2012.01.002

Source DB:  PubMed          Journal:  Acta Histochem        ISSN: 0065-1281            Impact factor:   2.479


  43 in total

1.  Paeoniflorin inhibits cell growth and induces cell cycle arrest through inhibition of FoxM1 in colorectal cancer cells.

Authors:  Meng Yue; Shiquan Li; Guoqiang Yan; Chenyao Li; Zhenhua Kang
Journal:  Cell Cycle       Date:  2018-01-05       Impact factor: 4.534

2.  FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis.

Authors:  Chen Huang; Jiawei Du; Keping Xie
Journal:  Biochim Biophys Acta       Date:  2014-01-11

3.  MicroRNA-211, a direct negative regulator of CDC25B expression, inhibits triple-negative breast cancer cells' growth and migration.

Authors:  Guo-qing Song; Yi Zhao
Journal:  Tumour Biol       Date:  2015-02-14

Review 4.  A review: hippo signaling pathway promotes tumor invasion and metastasis by regulating target gene expression.

Authors:  Hong-Li Li; Qian-Yu Li; Min-Jie Jin; Chao-Fan Lu; Zhao-Yang Mu; Wei-Yi Xu; Jian Song; Yan Zhang; Sai-Yang Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2021-04-17       Impact factor: 4.553

5.  Identification of key regulators associated with colon cancer prognosis and pathogenesis.

Authors:  Narges Toolabi; Fattane Sam Daliri; Amir Mokhlesi; Mahmood Talkhabi
Journal:  J Cell Commun Signal       Date:  2021-03-26       Impact factor: 5.782

6.  High FOXM1 expression was associated with bladder carcinogenesis.

Authors:  Dongye Liu; Zhe Zhang; Chui-ze Kong
Journal:  Tumour Biol       Date:  2013-01-17

7.  Prognostic significance of FoxM1 expression in non-small cell lung cancer.

Authors:  Qing Sun; Min Dong; Yujuan Chen; Jiawei Zhang; Jinpeng Qiao; Xuedan Guo
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

8.  FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.

Authors:  Masaaki Kuda; Kenichi Kohashi; Yuichi Yamada; Akira Maekawa; Yoshiaki Kinoshita; Tetsuya Nakatsura; Yukihide Iwamoto; Tomoaki Taguchi; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-11-09

9.  FOXM1 coming of age: time for translation into clinical benefits?

Authors:  Muy-Teck Teh
Journal:  Front Oncol       Date:  2012-10-15       Impact factor: 6.244

10.  Genome-wide mapping of FOXM1 binding reveals co-binding with estrogen receptor alpha in breast cancer cells.

Authors:  Deborah A Sanders; Caryn S Ross-Innes; Dario Beraldi; Jason S Carroll; Shankar Balasubramanian
Journal:  Genome Biol       Date:  2013-01-24       Impact factor: 13.583

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.